Market

Could Nomelcitinib Transform Plaque Psoriasis Care?
Research & Development Could Nomelcitinib Transform Plaque Psoriasis Care?

With more than 80 percent of trial participants achieving clear or almost clear skin, nomelcitinib is positioning itself as a robust competitor in the psoriasis treatment landscape. The quest for a highly effective, oral, and safe treatment for autoimmune skin conditions has long been the primary

Ethiopia Aims to Become Africa’s Pharmaceutical Hub by 2030
Management & Regulatory Ethiopia Aims to Become Africa’s Pharmaceutical Hub by 2030

Ethiopia's strategy reflects a broader continental trend toward health security, where local production is viewed as the only viable path to effective public health response. By 2030, the nation intends to transition from a major importer of medical goods to a self-reliant manufacturing powerhouse,

Data Brokers Track and Sell Private Mobile Health Location Data
Management & Regulatory Data Brokers Track and Sell Private Mobile Health Location Data

The lack of a comprehensive federal privacy mandate means that a consumer's protection against location tracking depends entirely on their specific state of residence. In the current landscape, the ubiquitous smartphone has evolved into a sophisticated surveillance tool that meticulously logs every

Why Did the $50 Million Victorian Hospital Tender Fail?
Management & Regulatory Why Did the $50 Million Victorian Hospital Tender Fail?

Systemic deficiencies in the digital bidding portal allowed sensitive commercial data to remain exposed from February until discovery in August 2026. This catastrophic oversight compromised a high-stakes procurement process managed by HealthShare Victoria, which was tasked with securing a

Peptide Access Moves Ahead of the Evidence
Management & Regulatory Peptide Access Moves Ahead of the Evidence

Hims & Hers now faces a potential peptide opportunity with a changed enforcement outlook but no new clinical evidence. Health and Human Services Secretary Robert F. Kennedy Jr. has introduced a policy under which HHS would refrain from enforcement against specified providers compounding six

Obesity Drug Advertising Faces a Moving Evidence Base
Management & Regulatory Obesity Drug Advertising Faces a Moving Evidence Base

U.S. District Judge Zahid Quraishi has declined Novo’s bid to halt Eli Lilly’s advertising comparisons between Zepbound and Wegovy. The decision rejects Novo’s request for a preliminary injunction; the underlying false-advertising dispute remains unresolved. For biopharma leaders, the case raises a

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later